A Phase I Study Evaluating the Single Subcutaneous Injection of Ebronucimab With Different Production Processes in Chinese Healthy Male Subjects
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Ebronucimab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Akeso Biopharma
- 21 Oct 2024 New trial record